Beximco Pharmaceuticals Limited (BST:R2WA)

Germany flag Germany · Delayed Price · Currency is EUR
0.4220
0.00 (0.00%)
At close: Jul 23, 2025
Market Cap329.43M
Revenue (ttm)373.79M
Net Income (ttm)51.25M
Shares Outn/a
EPS (ttm)0.11
PE Ratio6.43
Forward PE7.53
Dividend0.02 (5.91%)
Ex-Dividend DateNov 22, 2024
Volumen/a
Average Volume1,460
Open0.4280
Previous Close0.4220
Day's Range0.4220 - 0.4280
52-Week Range0.2260 - 0.4820
Betan/a
RSI52.92
Earnings DateNov 3, 2025

About Beximco Pharmaceuticals

Beximco Pharmaceuticals Limited manufactures and markets generic pharmaceutical formulations and active pharmaceutical ingredients in Bangladesh. The company provides allergic disorder, analgesics and antipyretic, anti-infective, antiviral, cardiovascular, central nervous system, cough and cold, endocrine and diabetes, eye care, gastrointestinal, hormone and steroid, intravenous fluid, musculoskeletal, oncology, respiratory, urogenital, skin care, vitamin and mineral supplement, and other products, as well as contract manufacturing services to ... [Read more]

Industry Pharmaceutical Preparations
Founded 1976
Employees 1,122
Stock Exchange Stuttgart Stock Exchange
Ticker Symbol R2WA
Full Company Profile

Financial Performance

In 2024, Beximco Pharmaceuticals's revenue was 44.39 billion, an increase of 13.05% compared to the previous year's 39.27 billion. Earnings were 5.83 billion, an increase of 26.34%.

Financial numbers in BDT Financial Statements

News

There is no news available yet.